ProMIS Neurosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

NET INCOME (LOSS) PER SHARE - Outstanding potentially dilutive common shares (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
NET LOSS PER SHARE
Dilutive common shares equivalents were excluded from the computation of diluted net income (loss) per share for the periods presented because including them would have been antidilutive	57,835,201	16,165,117	46,171,024	16,165,117
Employee Stock Option
NET LOSS PER SHARE
Dilutive common shares equivalents were excluded from the computation of diluted net income (loss) per share for the periods presented because including them would have been antidilutive	1,087,493	1,041,492	651,030	1,041,492
Warrants
NET LOSS PER SHARE
Dilutive common shares equivalents were excluded from the computation of diluted net income (loss) per share for the periods presented because including them would have been antidilutive	56,746,647	13,955,897	45,518,933	13,955,897
Series 1 Convertible Preferred Shares
NET LOSS PER SHARE
Dilutive common shares equivalents were excluded from the computation of diluted net income (loss) per share for the periods presented because including them would have been antidilutive		1,166,667		1,166,667
Deferred Share Units
NET LOSS PER SHARE
Dilutive common shares equivalents were excluded from the computation of diluted net income (loss) per share for the periods presented because including them would have been antidilutive	1,061	1,061	1,061	1,061